Pharming Group N.V. Files 6-K with Press Release
Ticker: PHAR · Form: 6-K · Filed: Oct 1, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, press-release
TL;DR
Pharming Group N.V. dropped a 6-K with a press release on Oct 1st - check Exhibit 99.1 for details.
AI Summary
Pharming Group N.V. filed a Form 6-K on October 1, 2025, to furnish a press release dated October 1, 2025. The filing itself does not contain specific financial details or operational updates beyond the fact that a press release is being provided as Exhibit 99.1.
Why It Matters
This filing indicates that Pharming Group N.V. is providing an update to the SEC, likely containing material information for investors, though the specifics are in the attached press release.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a press release and does not contain immediate financial or operational risks.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- October 1, 2025 (date) — Filing and Press Release Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release dated October 1, 2025, as Exhibit 99.1.
What is the exact name of the company filing this report?
The exact name of the company is Pharming Group N.V.
On what date was this Form 6-K filed?
This Form 6-K was filed on October 1, 2025.
What exhibit number is associated with the press release?
The press release is furnished as Exhibit 99.1.
Does this filing require an annual report under Form 20-F or 40-F?
Yes, the registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 1,582 words · 6 min read · ~5 pages · Grade level 11.4 · Accepted 2025-10-01 06:11:38
Filing Documents
- pharminggroupannouncesusfd.htm (6-K) — 38KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-25-000043.txt ( ) — 206KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred t